For adult periodontitis. ANDA 65277, held by Chartwell Molecular. Doxycycline Hyclate.
As of Nov 21, 2026, ANDA 65277 (Doxycycline Hyclate), held by Chartwell Molecular, was first approved by FDA on Nov 10, 2005, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Doxycycline hyclate tablets are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline Hyclate Tablets, USP and other antibacterial drugs, Doxycycline Hyclate Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 10, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 20MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 23Labeling · Standard review | Approved | None posted |
| Dec 13, 2007 | Supplement 3Labeling | Approved | None posted |
| Nov 10, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters